Home
/
Aquestive Therapeutics, Inc.
/
Financials
/
Quarterly
Aquestive Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Aquestive Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2018
Sep 30, 2018
$13.27M
Nov 6, 2018
Q2
2018
Jun 30, 2018
$13.93M
Sep 4, 2018
Q3
2018
Sep 30, 2017
$27.15M
Nov 6, 2018
Q2
2018
Jun 30, 2017
$11.14M
Sep 4, 2018
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$12.81M
Nov 5, 2025
Q2
2025
Jun 30, 2025
$10.00M
Aug 11, 2025
Q1
2025
Mar 31, 2025
$8.72M
May 12, 2025
Q3
2025
Sep 30, 2024
$13.54M
Nov 5, 2025
Q2
2025
Jun 30, 2024
$20.10M
Aug 11, 2025
Q1
2025
Mar 31, 2024
$12.05M
May 12, 2025
Q3
2024
Sep 30, 2023
$13.00M
Nov 4, 2024
Q2
2024
Jun 30, 2023
$13.24M
Aug 6, 2024
Q1
2024
Mar 31, 2023
$11.13M
May 7, 2024
Q3
2023
Sep 30, 2022
$11.46M
Nov 6, 2023
Q2
2023
Jun 30, 2022
$13.27M
Aug 7, 2023
Q1
2023
Mar 31, 2022
$12.27M
May 2, 2023
Q3
2022
Sep 30, 2021
$13.29M
Nov 1, 2022
Q2
2022
Jun 30, 2021
$15.35M
Aug 2, 2022
Q1
2022
Mar 31, 2021
$11.12M
May 4, 2022
Q3
2021
Sep 30, 2020
$8.26M
Nov 2, 2021
Q2
2021
Jun 30, 2020
$21.68M
Aug 3, 2021
Q1
2021
Mar 31, 2020
$8.77M
May 4, 2021
Q3
2020
Sep 30, 2019
$12.42M
Nov 4, 2020
Q2
2020
Jun 30, 2019
$11.13M
Aug 4, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($15.45M)
Nov 5, 2025
Q2
2025
Jun 30, 2025
($13.55M)
Aug 11, 2025
Q3
2025
Jun 30, 2025
($13.55M)
Nov 5, 2025
Q2
2025
Mar 31, 2025
($22.93M)
Aug 11, 2025
Q1
2025
Mar 31, 2025
($22.93M)
May 12, 2025
Q3
2025
Mar 31, 2025
($22.93M)
Nov 5, 2025
Q3
2025
Sep 30, 2024
($11.51M)
Nov 5, 2025
Q2
2025
Jun 30, 2024
($2.75M)
Aug 11, 2025
Q3
2025
Jun 30, 2024
($2.75M)
Nov 5, 2025
Q1
2025
Mar 31, 2024
($12.83M)
May 12, 2025
Q2
2025
Mar 31, 2024
($12.83M)
Aug 11, 2025
Q3
2025
Mar 31, 2024
($12.83M)
Nov 5, 2025
Q3
2024
Sep 30, 2023
($2.04M)
Nov 4, 2024
Q3
2024
Jun 30, 2023
($5.79M)
Nov 4, 2024
Q2
2024
Jun 30, 2023
($5.79M)
Aug 6, 2024
Q2
2024
Mar 31, 2023
$8.07M
Aug 6, 2024
Q3
2024
Mar 31, 2023
$8.07M
Nov 4, 2024
Q1
2024
Mar 31, 2023
$8.07M
May 7, 2024
Q3
2023
Sep 30, 2022
($12.54M)
Nov 6, 2023
Q2
2023
Jun 30, 2022
($16.30M)
Aug 7, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($11.48M)
Nov 5, 2025
Q2
2025
Jun 30, 2025
($11.37M)
Aug 11, 2025
Q1
2025
Mar 31, 2025
($19.37M)
May 12, 2025
Q3
2025
Sep 30, 2024
($8.29M)
Nov 5, 2025
Q2
2025
Jun 30, 2024
$55.0K
Aug 11, 2025
Q1
2025
Mar 31, 2024
($8.96M)
May 12, 2025
Q3
2024
Sep 30, 2023
($2.38M)
Nov 4, 2024
Q2
2024
Jun 30, 2023
($4.21M)
Aug 6, 2024
Q1
2024
Mar 31, 2023
($4.61M)
May 7, 2024
Q3
2023
Sep 30, 2022
($8.85M)
Nov 6, 2023
Q2
2023
Jun 30, 2022
($12.76M)
Aug 7, 2023
Q1
2023
Mar 31, 2022
($9.74M)
May 2, 2023
Q3
2022
Sep 30, 2021
($7.97M)
Nov 1, 2022
Q2
2022
Jun 30, 2021
($6.52M)
Aug 2, 2022
Q1
2022
Mar 31, 2021
($8.53M)
May 4, 2022
Q3
2021
Sep 30, 2020
($13.78M)
Nov 2, 2021
Q2
2021
Jun 30, 2020
$395.0K
Aug 3, 2021
Q1
2021
Mar 31, 2020
($13.86M)
May 4, 2021
Q3
2020
Sep 30, 2019
($11.00M)
Nov 4, 2020
Q2
2020
Jun 30, 2019
($18.69M)
Aug 4, 2020